Clearside's series C brings $20M

Ophthalmology company Clearside Biomedical Inc. (Alpharetta, Ga.) raised $20 million in a series C round from new investors Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital as well as existing investors RusnanoMedInvest, Hatteras Venture Partners, Mountain Group Capital and Georgia Research Alliance Venture Fund.

Clearside is enrolling patients in the Phase III Peachtree trial of CLS-TA ( CLS-1001), a formulation of triamcinolone acetonide delivered using the company's ocular microinjection platform, to treat macular edema associated with non-infectious uveitis. ...